Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Data To Support Food and Nutrition Product Communications, as Used by the Food and Drug Administration, 29760-29762 [2011-12557]
Download as PDF
29760
Federal Register / Vol. 76, No. 99 / Monday, May 23, 2011 / Notices
which may in turn affect their dietary
choices. Results of the study will not be
used to develop population estimates.
To help design and refine the
questionnaire, FDA plans to conduct
cognitive interviews by screening 72
panelists in order to obtain 9
participants in the interviews. Each
screening is expected to take 5 minutes
(0.083 hour) and each cognitive
interview is expected to take 1 hour.
The total for cognitive interview
activities is 15 hours (6 hours + 9
hours). Subsequently, we plan to
conduct pretests of the questionnaire
before it is administered in the study.
We expect that 1,600 invitations, each
taking 2 minutes (0.033 hour), will need
to be sent to panelists to have 200 of
them complete a 15-minute (0.25 hour)
pretest. The total for the pretest
activities is 103 hours (53 hours + 50
hours). For the survey, we estimate that
80,000 invitations, each taking 2
minutes (0.033 hour) to complete, will
need to be sent to the consumer panel
to have 10,000 of its members complete
a 15-minute (0.25 hour) questionnaire.
The total for the survey activities is
5,140 hours (2,640 hours + 2,500 hours).
Thus, the total estimated burden is
5,258 hours. FDA’s burden estimate is
based on prior experience with research
that is similar to this proposed study.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number of
respondents
Number of responses per
respondent
Total annual
responses
Average
burden per
response
(in hours) 2
Cognitive interview screener ................................................
Cognitive interview ...............................................................
Pretest invitation ..................................................................
Pretest ..................................................................................
Survey invitation ...................................................................
Survey ..................................................................................
Total ..............................................................................
72
9
1,600
200
80,000
10,000
........................
1
1
1
1
1
1
........................
72
9
1,600
200
80,000
10,000
........................
5/60
1
2/60
15/60
2/60
15/60
........................
1 There
Total hours
6
9
53
50
2,640
2,500
5,258
are no capital costs or operating and maintenance costs associated with this collection of information.
estimates of less than 1 hour are expressed as a fraction of an hour in the format ‘‘[number of minutes per response]/60’’.
2 Burden
srobinson on DSK4SPTVN1PROD with NOTICES
II. References
The following references are on
display in the Division of Dockets
Management (see ADDRESSES) and may
be seen by interested persons between 9
a.m. and 4 p.m., Monday through
Friday.
1. Levy, A.S., Fein, S.B., and Schucker, R.E.
‘‘Nutrition Labeling Formats:
Performance and Preference,’’ Food
Technology, 45: 116–121, 1991.
2. Levy, A.S., Fein, S.B., and Schucker, R.E.
‘‘More Effective Nutrition Label Formats
Are Not Necessarily Preferred,’’ Journal
of the American Dietetic Association, 92:
1230–1234, 1992.
3. Levy, A.S., Fein, S.B., and Schucker, R.E.
‘‘Performance Characteristics of Seven
Nutrition Label Formats,’’ Journal of
Public Policy and Marketing, 15: 1–15,
1996.
4. Lando, A.M. and Labiner-Wolfe, J.
‘‘Helping Consumers to Make More
Healthful Food Choices: Consumer
Views on Modifying Food Labels and
Providing Point-of-Purchase Nutrition
Information at Quick-Service
Restaurants,’’ Journal of Nutrition
Education and Behavior, 39: 157–163,
2007.
5. U.S. Food and Drug Administration.
Calories Count: Report of the Working
Group on Obesity, 2004, available at
https://www.fda.gov/Food/
LabelingNutrition/ReportsResearch/
ucm081696.htm.
6. U.S. Food and Drug Administration. ‘‘2008
Health and Diet Survey—Preliminary
Topline Frequencies (Weighted),’’ 2010,
available at https://www.fda.gov/Food/
ScienceResearch/ResearchAreas/
ConsumerResearch/ucm193895.htm.
VerDate Mar<15>2010
16:22 May 20, 2011
Jkt 223001
7. Li, F., Miniard, P.W., and Barone, M.J.
‘‘The Facilitating Influence of Consumer
Knowledge on the Effectiveness of Daily
Value Reference Information,’’ Journal of
the Academy of Marketing Science, 28:
425–436, 2000.
8. Levy, L., Patterson, R.E., Kristal, A.R., and
Li, S.S. ‘‘How Well Do Consumers
Understand Percentage Daily Value on
Food Labels?’’ American Journal of
Health Promotion, 14: 157–160, 2000.
9. Institute of Medicine. Dietary Reference
Intakes: Guiding Principles for Nutrition
Labeling and Fortification. Washington,
DC: National Academies Press, 2003.
Dated: May 16, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–12556 Filed 5–20–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0640]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Data To Support
Food and Nutrition Product
Communications, as Used by the Food
and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
PO 00000
Notice.
Frm 00041
Fmt 4703
Sfmt 4703
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
SUMMARY:
Fax written comments on the
collection of information by June 22,
2011.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
title ‘‘Data to Support Food and
Nutrition Product Communications, as
Used by the Food and Drug
Administration.’’ Also include the FDA
docket number found in brackets in the
heading of this document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\23MYN1.SGM
23MYN1
29761
Federal Register / Vol. 76, No. 99 / Monday, May 23, 2011 / Notices
Data To Support Food and Nutrition
Product Communications, as Used by
the Food and Drug Administration—
(OMB Control Number 0910–NEW)
FDA plans to use the data collected
under this generic clearance to inform
its nutrition and foods communications
campaigns. FDA expects the data to
guide the formulation of its food and
nutrition communication objectives.
FDA also plans to use the data to help
tailor print, broadcast, and use
electronic media communications in
order for them to have powerful and
desired impacts on target audiences.
The data will not be used for the
purposes of making policy or regulatory
decisions.
The information collected will serve
two major purposes. First, as formative
research, it will provide the critical
knowledge needed about target
audiences. FDA must explore
audiences’ beliefs, perceptions, and
decisionmaking processes about
nutrition and food consumption in
order to formulate the basic objectives of
its risk communication campaigns. Such
knowledge will provide the needed
target audience understanding to design
effective communication strategies,
messages, and product labels. These
communications will aim to improve
public understanding of the risks and
benefits of consuming certain foods or
nutritional products by providing users
with a better context in which to place
risk information more completely.
Second, as initial testing, it will give
FDA some information about the
potential effectiveness of messages and
materials in reaching and successfully
communicating with their intended
audiences. Testing messages with a
sample of the target audience will allow
FDA to refine messages while still in the
developmental stage. Respondents may
be asked to give their reaction to the
messages in individual or group
settings.
FDA’s Center of Food Safety and
Applied Nutrition, Office of the
Commissioner, and other Centers or
Offices will use this mechanism to test
messages about regulated food and
nutrition products on a variety of
subjects related to consumer, patient, or
health care professional perceptions and
use of foods and related materials,
including but not limited to, food
advertising, food and nutrition labeling,
emerging risk communications, online
sales of food products, and consumer
and professional education. The data
will not be used for the purposes of
making policy or regulatory decisions.
In the Federal Register of December
29, 2010 (75 FR 82030), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. FDA received one
comment. It complimented the data
collection tools that FDA proposed to
use within this clearance and suggested
use of newer technologies to improve
data collection. It also noted that
automated survey data collection (audio
computer-assisted self interview, for
example) does not reduce respondent
burden, which FDA acknowledges. The
other parts of the comment were beyond
the scope of the questions asked in the
60-day Federal Register notice.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Individual indepth interviews ................................................
General public focus group interviews ................................
Intercept interviews:
Central location .............................................................
Intercept interviews:
Telephone .....................................................................
Self-Administered surveys ...................................................
Gatekeeper reviews .............................................................
Omnibus surveys .................................................................
Number of
responses per
respondent
Average
burden per
response
(in hours) 2
Total annual
responses
Total hours
360
144
1
1
360
144
45/60
1 30/60
270
216
600
1
600
15/60
150
10,000 3
2,400
400
2,400
1
1
1
1
10,000
2,400
400
2,400
5/60
15/60
30/60
10/60
800
600
200
408
Total (General public) ...................................................
16,304
........................
16,304
........................
2,644
Total Physician focus group interviews ...............................
144
1
144
1 30/60
216
Total (Overall) ...............................................................
........................
........................
........................
........................
2,860
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
estimates of less than 1 hour are expressed as a fraction of an hour in the format ‘‘[number of minutes per response]/60’’.
interviews with callers to test messages, concepts, and strategies following their call-in request to an FDA Center 1–800 number.
2 Burden
srobinson on DSK4SPTVN1PROD with NOTICES
3 Brief
VerDate Mar<15>2010
16:22 May 20, 2011
Jkt 223001
PO 00000
Frm 00042
Fmt 4703
Sfmt 9990
E:\FR\FM\23MYN1.SGM
23MYN1
29762
Federal Register / Vol. 76, No. 99 / Monday, May 23, 2011 / Notices
Annually, FDA projects about 30
communication studies using the
variety of test methods listed in table 1.
FDA is requesting this burden so as not
to restrict the Agency’s ability to gather
information on public sentiment for its
proposals in its regulatory and
communications programs.
Dated: May 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–12557 Filed 5–20–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0307]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Antiparasitic
Resistance and Combination New
Animal Drugs Survey
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(the PRA).
DATES: Fax written comments on the
collection of information by June 22,
2011.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
title ‘‘Antiparasitic Resistance and
Combination New Animal Drugs
Survey.’’ Also include the FDA docket
number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, 301–
796–7651,
juanmanuel.vilela@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:22 May 20, 2011
Jkt 223001
has submitted the following proposed
collection of information to OMB for
review and clearance.
Antiparasitic Resistance and
Combination New Animal Drugs
Survey—(OMB Control Number 0910–
NEW)
Resistance of parasites to one or more
of the major classes of FDA approved
antiparasitic drugs is a documented
problem in cattle, horses, sheep, and
goats in the United States. Further, FDA
is aware that there are differing
scientific opinions on the impact of the
use of multiple antiparasitic drugs at the
same time on the development of
resistance to these drugs. The results
from this survey will assist FDA in
regulating antiparasitic drugs. FDA will
also share their results with the
veterinary parasitology community.
FDA plans to survey scientists and
veterinarians with expertise in
veterinary parasitology using a Webbased tool. The questions in the survey
are designed to elicit expert opinions
and clarify areas of agreement and
disagreement within the veterinary
parasitology community. The survey
will query subjects on topics such as: (1)
Concurrent use of multiple antiparasitic
drug products, (2) recommended tests to
detect and monitor for antiparasitic
resistance, (3) characteristics of
combination antiparasitic drug products
that may either slow or enhance the
selection for multidrug resistant
parasites, and (4) regulatory
considerations regarding combination
antiparasitic drugs.
In the Federal Register of July 13,
2010 (75 FR 39948), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. FDA received five
comments (all from the same source).
(Comment 1) The first comment stated
that any conclusions drawn from a
survey that includes a diversity of
opinion and conjecture would not be
appropriate or adequate to develop the
Agency’s position with respect to the
regulation of antiparasitic drugs. The
Agency should instead consult with
appropriate experts in the field to
develop an appropriate science-based
strategy.
(Center for Veterinary Medicine’s
(CVM’s) Response) The proposed
information collection is only one part
of a strategy to compile scientific data
on the subject of antiparasitic resistance
and combinations. It is not the sole
method by which the Agency will make
any regulatory decisions. The other
parts of the strategy include gathering
information from scientific meetings,
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
consultation with outside experts, and a
comprehensive literature search and
evaluation. The information collection
allows the Agency to gauge the
awareness of the issues and affords a
broader audience with an opportunity to
provide scientific information to the
Agency about the current state of
antiparasitic resistance, the use patterns
of combinations of antiparasitic drugs,
and measures being employed in the
field to detect and curtail antiparasitic
resistance.
(Comment 2) The second comment
requested that FDA publish the survey
questions in the Federal Register for
comment prior to finalizing them for the
pretest and the actual survey.
(CVM’s Response) In accordance with
the PRA and the requirements of OMB,
FDA will publish the survey questions
as part of a 30-day notice in the Federal
Register, and the public will have the
opportunity to comment.
(Comment 3) The third comment
requested that FDA comment on how
FDA will decide who to survey.
(CVM’s Response) FDA will offer the
Web-based survey to scientists and
veterinarians with parasitology
experience. Professional organizations
that FDA will notify of the availability
of the survey include the American
Veterinary Medical Association,
American Academy of Veterinary
Pharmacology and Therapeutics,
American College of Veterinary Internal
Medicine, American Association of
Veterinary Parasitologists, World
Association for the Advancement of
Veterinary Parasitology, American
Association of Bovine Practitioners,
American Association of Equine
Practitioners, American Association of
Small Ruminant Practitioners, and the
Veterinary Information Network.
Additional organizations may be invited
as appropriate.
(Comment 4) The fourth comment
requested that FDA comment on who
will review and compile the survey
results.
(CVM’s Response) Veterinarians and
other scientists from CVM will review
and compile the survey results.
(Comment 5) The fifth comment
requested that FDA comment on how
FDA plans to publish the results and
how they will be made public.
(CVM’s Response) FDA plans to
present a summary of the information
collection at a scientific forum widely
available to the veterinary parasitology
community.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\23MYN1.SGM
23MYN1
Agencies
[Federal Register Volume 76, Number 99 (Monday, May 23, 2011)]
[Notices]
[Pages 29760-29762]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-12557]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0640]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Data To Support Food
and Nutrition Product Communications, as Used by the Food and Drug
Administration
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by June
22, 2011.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-NEW and
title ``Data to Support Food and Nutrition Product Communications, as
Used by the Food and Drug Administration.'' Also include the FDA docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
[[Page 29761]]
Data To Support Food and Nutrition Product Communications, as Used by
the Food and Drug Administration--(OMB Control Number 0910-NEW)
FDA plans to use the data collected under this generic clearance to
inform its nutrition and foods communications campaigns. FDA expects
the data to guide the formulation of its food and nutrition
communication objectives. FDA also plans to use the data to help tailor
print, broadcast, and use electronic media communications in order for
them to have powerful and desired impacts on target audiences. The data
will not be used for the purposes of making policy or regulatory
decisions.
The information collected will serve two major purposes. First, as
formative research, it will provide the critical knowledge needed about
target audiences. FDA must explore audiences' beliefs, perceptions, and
decisionmaking processes about nutrition and food consumption in order
to formulate the basic objectives of its risk communication campaigns.
Such knowledge will provide the needed target audience understanding to
design effective communication strategies, messages, and product
labels. These communications will aim to improve public understanding
of the risks and benefits of consuming certain foods or nutritional
products by providing users with a better context in which to place
risk information more completely.
Second, as initial testing, it will give FDA some information about
the potential effectiveness of messages and materials in reaching and
successfully communicating with their intended audiences. Testing
messages with a sample of the target audience will allow FDA to refine
messages while still in the developmental stage. Respondents may be
asked to give their reaction to the messages in individual or group
settings.
FDA's Center of Food Safety and Applied Nutrition, Office of the
Commissioner, and other Centers or Offices will use this mechanism to
test messages about regulated food and nutrition products on a variety
of subjects related to consumer, patient, or health care professional
perceptions and use of foods and related materials, including but not
limited to, food advertising, food and nutrition labeling, emerging
risk communications, online sales of food products, and consumer and
professional education. The data will not be used for the purposes of
making policy or regulatory decisions.
In the Federal Register of December 29, 2010 (75 FR 82030), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. FDA received one comment. It complimented
the data collection tools that FDA proposed to use within this
clearance and suggested use of newer technologies to improve data
collection. It also noted that automated survey data collection (audio
computer-assisted self interview, for example) does not reduce
respondent burden, which FDA acknowledges. The other parts of the
comment were beyond the scope of the questions asked in the 60-day
Federal Register notice.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
respondents responses per responses response (in Total hours
respondent hours) \2\
----------------------------------------------------------------------------------------------------------------
Individual indepth interviews... 360 1 360 45/60 270
General public focus group 144 1 144 1 30/60 216
interviews.....................
Intercept interviews:
Central location............ 600 1 600 15/60 150
Intercept interviews:
Telephone................... 10,000 \3\ 1 10,000 5/60 800
Self-Administered surveys....... 2,400 1 2,400 15/60 600
Gatekeeper reviews.............. 400 1 400 30/60 200
Omnibus surveys................. 2,400 1 2,400 10/60 408
-------------------------------------------------------------------------------
Total (General public)...... 16,304 .............. 16,304 .............. 2,644
===============================================================================
Total Physician focus group 144 1 144 1 30/60 216
interviews.....................
-------------------------------------------------------------------------------
Total (Overall)............. .............. .............. .............. .............. 2,860
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Burden estimates of less than 1 hour are expressed as a fraction of an hour in the format ``[number of
minutes per response]/60''.
\3\ Brief interviews with callers to test messages, concepts, and strategies following their call-in request to
an FDA Center 1-800 number.
[[Page 29762]]
Annually, FDA projects about 30 communication studies using the
variety of test methods listed in table 1. FDA is requesting this
burden so as not to restrict the Agency's ability to gather information
on public sentiment for its proposals in its regulatory and
communications programs.
Dated: May 17, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-12557 Filed 5-20-11; 8:45 am]
BILLING CODE 4160-01-P